Search

Your search keyword '"Chen DY"' showing total 1,497 results
Start Over Author "Chen DY"
1,497 results on '"Chen DY"'

1. Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients

Author

Tu ZH, Jin PB, Chen DY, Chen ZY, Li ZW, Wu J, Lou B, Zhang BS, Zhang L, Zhang W, and Liang TB

Subjects
liver transplantation, 2019-ncov vaccination, sars-cov-2 infection, disease control, epidemiology, immune responses, Infectious and parasitic diseases, RC109-216
Abstract

Zhen-Hua Tu,1,* Ping-Bo Jin,1,* Di-Yu Chen,1 Zhi-Yun Chen,1 Zhi-Wei Li,1 Jie Wu,2 Bin Lou,3 Bao-Shan Zhang,4 Lin Zhang,1 Wei Zhang,1 Ting-Bo Liang1,5– 7 1Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou, 310003, People’s Republic of China; 3Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 4Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 5Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 6Zhejiang Province Innovation Center for the Study of Pancreatic Diseases, Hangzhou, 310003, People’s Republic of China; 7Zhejiang University Cancer Center, Hangzhou, 310003, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ting-Bo Liang, Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China, Tel +86 571 8723 6601, Fax +86 571 8707 2577, Email liangtingbo@zju.edu.cnPurpose: To evaluate the response and safety of an inactivated vaccine (Sinovac Life Sciences Co., Ltd., Beijing, China) for coronavirus disease 2019 (COVID-19) in liver transplant (LTx) recipients from China.Patients and Methods: Thirty-five recipients post LTx from the First Affiliated Hospital of Zhejiang University School of Medicine who received inactivated vaccine from June to October 2021 were screened. Information regarding vaccine side effects and clinical data were collected.Results: Thirty-five LTx recipients were enrolled, with a mean age of 46 years, and most patients were male (30, 85.71%). All the participants had a negative history of COVID-19 infection. Predictors for negative response in the recipients were interleukin-2 receptor (IL-2R) induction during LTx, shorter time post LTx and application of a derivative from mycophenolate acid (MPA). No serious adverse events were observed during the progress of vaccination or after the vaccination.Conclusion: LTx recipients have a substantially partial immunological response to the inactivated vaccine for COVID-19. IL-2R induction during LTx, a shorter time post LTx and the application of a derivative from MPA seem to be predictors for a negative serological immunoglobulin G (IgG) antibody response in recipients. The findings require booster vaccination in these LTx recipients.Keywords: liver transplantation, 2019-nCoV vaccination, SARS-CoV-2 infection, disease control, epidemiology, immune responses

Published
2022

2. Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury

Author

Liu YH, Guo Y, Xu H, Feng H, and Chen DY

Subjects
non-alcoholic simple fatty liver disease, antituberculosis drugs, drug-induced liver injury, Infectious and parasitic diseases, RC109-216
Abstract

Yi-Hui Liu,1 Yan Guo,2 Hong Xu,1 Hui Feng,1 Dong-Ya Chen1 1Department of Digestive Hepatology, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, 310003, People’s Republic of China; 2Department of Gastroenterology, Hangzhou Third Hospital, Hangzhou, Zhejiang, 310009, People’s Republic of ChinaCorrespondence: Yi-Hui LiuDepartment of Digestive Hepatology, Hangzhou Red Cross Hospital, No. 208 of Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, 310003, People’s Republic of ChinaTel +8613588227972Email yhl_123drsea@163.comObjective: To observe the effect of non-alcoholic simple fatty liver disease on drug-induced liver injury caused by tuberculosis.Methods: We retrospectively analyzed the incidence, characteristics, and risk factors of antituberculosis drug-induced liver injury in 104 patients with initial treatment of tuberculosis complicated with non-alcoholic simple fatty liver disease. The patients were divided into two groups according to whether there was liver injury or not. The differences in age, gender, body mass index (BMI), cholesterol, and triglycerides were studied between the two groups.Results: Among the 104 patients with initial treatment of tuberculosis complicated with non-alcoholic fatty liver disease, 24 (23%) patients developed a drug-induced liver injury. The remaining 80 (77%) patients did not develop drug-induced liver injury (χ2 = 60.308, P < 0.05). In the liver injury group, there were 20 cases of mild liver injury, two cases of moderate liver injury, two cases of severe liver injury, 22 cases of hepatocellular injury, two cases of cholestasis, and no cases of mixed liver injury. The time of abnormal liver function in antituberculosis treatment was 16.42 ± 9.18 days from the beginning of the antituberculosis treatment. There were no significant differences in gender, age, BMI, or triglyceride between the liver injury group and the non-liver injury group (χ2 = 2.063, t = 0.179, t = 0.703, t = 1.12, P > 0.05 in all), but there were significant differences in cholesterol (t = 3.08, P < 0.05). By logistic regression analysis, cholesterol was a high-risk factor for liver injury.Conclusion: Non-alcoholic simple fatty liver disease may increase the risk of antituberculosis drug-induced liver injury.Keywords: non-alcoholic simple fatty liver disease, antituberculosis drugs, drug-induced liver injury

Published
2021

3. Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients

Author

Chen HH, Chen DY, Lin CC, Chen YM, Lai KL, and Lin CH

Subjects
ankylosing spondylitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, diabetes mellitus, Therapeutics. Pharmacology, RM1-950
Abstract

Hsin-Hua Chen,1–7 Der-Yuan Chen,1–6 Chi-Chen Lin,1,2 Yi-Ming Chen,1–4 Kuo-Lung Lai,3,4 Ching-Heng Lin1 1Department of Medical Research, Taichung Veterans General Hospital, 2Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, Chung-Hsing University, Taichung, 3School of Medicine, National Yang-Ming University, Taipei, 4Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, 5School of Medicine, Chung-Shan Medical University, 6Department of Medical Education, Taichung Veterans General Hospital, Taichung, 7Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan Purpose: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA).Patients and methods: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs. Multivariable analysis was used to estimate the effect of different therapies on the risk of DM.Results: The incidence rates of DM per 1,000 person-years were 8.3 for users of anti-TNF drugs, 13.3 for users of cyclosporine (CSA), 8.4 for users of hydroxychloroquine (HCQ), and 8.1 for users of other nonbiologic DMARDs. Compared with the users of nonbiologic DMARDs, the multivariate-adjusted hazard ratios (aHRs) for DM were significantly lower for those who used anti-TNF drugs with HCQ (aHR: 0.49, 95% confidence interval [CI]: 0.36–0.66) and those who used HCQ alone (aHR: 0.70, 95% CI: 0.63–0.78), but not for those who used anti-TNFs without HCQ (aHR: 1.23, 95% CI: 0.94–1.60) or CSA (aHR: 1.14, 95% CI: 0.77–1.70).Conclusion: The aHR for DM was lowest for patients with RA and PS/PSA who initiated treatment with an anti-TNF agent with concomitant HCQ, followed by HCQ users. Those who used anti-TNF agents without HCQ and other nonbiologic DMARDs had a similar risk of DM. Keywords: ankylosing spondylitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, diabetes mellitus

Published
2017

4. Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

Author

Chen HH, Chen DY, Chen YM, and Tang CH

Subjects
adalimumab, etanercept, methotrexate, rheumatoid arthritis, treatment discontinuation, Medicine (General), R5-920
Abstract

Hsin-Hua Chen,1–6 Der-Yuan Chen,1–3,6–8 Yi-Ming Chen,1–3 Chao-Hsiun Tang9 1Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China; 2School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China; 3Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China; 4Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taiwan, Republic of China; 5Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan, Republic of China; 6School of Medicine, Chung-Shan Medical University, Taichung, Taiwan, Republic of China; 7Institute of Biomedical Science, Chung-Hsing University, Taichung, Taiwan, Republic of China; 8Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan, Republic of China; 9School of Health Care Administration, Taipei Medical University, Taipei, Taiwan, Republic of China Objective: To compare drug discontinuation risk between adalimumab (ADA) and etanercept (ETN) treatment among anti-tumor necrosis factor (anti-TNF)-naïve rheumatoid arthritis (RA) patients, in particular the influence of concomitant dose of methotrexate (MTX).Methods: This retrospective nationwide population-based cohort study identified 4,592 anti-TNF-naïve RA patients in whom ETN (n=2,609) or ADA (n=1,983) was initiated using National Health Insurance claims data. After adjustment for prior medication, concomitant medication, and baseline demographic data, the relative risk of drug discontinuation in ADA users compared with ETN users was quantified by calculating adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) using Cox proportional hazard regression analyses, stratified by the follow-up time (≤1 year, >1 year) and/or concomitant MTX dose (≤10 mg/wk, >10 mg/wk).Results: ADA users had a higher risk of drug discontinuation compared with ETN users during the first year of follow-up (aHR, 1.13; 95% CI, 1.01–1.27), but not during all treatment periods (aHR, 1.06; 95% CI, 0.98–1.16) or after 1 year (aHR, 0.99; 95% CI, 0.87–1.13). However, ADA users had a significantly higher risk of drug discontinuation compared with ETN users among patients on concomitant MTX >10 mg/wk during all treatment periods (aHR, 1.27; 95% CI, 1.10–1.47), during the first year of follow-up (aHR, 1.48; 95% CI, 1.22–1.78), or after 1 year (aHR, 1.42; 95% CI, 1.06–1.90), but not among patients on concomitant MTX 0–10 mg/wk.Conclusion: This population-based cohort study demonstrated a modification effect of concomitant MTX dose on the relative risk of anti-TNF discontinuation for ADA compared with ETN among anti-TNF-naïve RA patients. However, the lack of exact cause of anti-TNF discontinuation limited causal inference of such a concomitant MTX dose-related modification effect. Keywords: adalimumab, etanercept, methotrexate, rheumatoid arthritis, treatment disconti­nuation

Published
2016

5. A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration

Author

Sun CL, Wang XL, Zheng ZZ, Chen DY, Wang XQ, Shi F, Yu DH, and Wu H

Subjects
Medicine (General), R5-920
Abstract

Changling Sun,1,3,* Xueling Wang,1,* Zhaozhu Zheng,2 Dongye Chen,1 Xiaoqin Wang,2 Fuxin Shi,1 Dehong Yu,1 Hao Wu11Department of Otolaryngology–Head and Neck Surgery, Xinhua Hospital, Ear Institute, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, 2National Engineering Laboratory for Modern Silk, Soochow University, Suzhou, 3Department of Otolaryngology–Head and Neck Surgery, Affiliated Hospital of Jiangnan University, The Fourth People’s Hospital of Wuxi City, Wuxi, People’s Republic of China*These authors have contributed equally to this workAbstract: This study aimed to investigate the sustained drug release properties and hearing protection effect of polyethylene glycol-coated polylactic acid (PEG-PLA) stealth nanoparticles loaded with dexamethasone (DEX). DEX was fabricated into PEG-PLA nanoparticles using an emulsion and evaporation technique, as previously reported. The DEX-loaded PEG-PLA nanoparticles (DEX-NPs) had a hydrodynamic diameter of 130±4.78 nm, and a zeta potential of -26.13±3.28 mV. The in vitro release of DEX from DEX-NPs lasted 24 days in phosphate buffered saline (pH 7.4), 5 days in artificial perilymph (pH 7.4), and 1 day in rat plasma. Coumarin 6-labeled NPs placed onto the round window membrane (RWM) of guinea pigs penetrated RWM quickly and accumulated to the organs of Corti, stria vascularis, and spiral ganglion cells after 1 hour of administration. The DEX-NPs locally applied onto the RWM of guinea pigs by a single-dose administration continuously released DEX in 48 hours, which was significantly longer than the free DEX that was cleared out within 12 hours after administration at the same dose. Further functional studies showed that locally administrated single-dose DEX-NPs effectively preserved outer hair cells in guinea pigs after cisplatin insult and thus significantly attenuated hearing loss at 4 kHz and 8 kHz frequencies when compared to the control of free DEX formulation. Histological analyses indicated that the administration of DEX-NPs did not induce local inflammatory responses. Therefore, prolonged delivery of DEX by PEG-PLA nanoparticles through local RWM diffusion (administration) significantly protected the hair cells and auditory function in guinea pigs from cisplatin toxicity, as determined at both histological and functional levels, suggesting the potential therapeutic benefits in clinical applications.Keywords: stealth nanoparticles, dexamethasone, single-dose administration, cisplatin-induced hearing loss

Published
2015

6. Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

Author

Plimack ER, Yu JQ, Chen DY, and Smaldone MC

Subjects
Medicine (General), R5-920
Abstract

Marc C Smaldone,1 David YT Chen,1 Jian Q Yu,2 Elizabeth R Plimack31Division of Urologic Oncology, 2Department of Diagnostic Imaging, 3Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Renal cell carcinoma (RCC) is a biologically heterogeneous disease, with many small renal masses (SRMs) exhibiting an indolent natural history, while others progress more rapidly to become life-threatening. Existing multiphase contrast-enhanced imaging methods, such as computed tomography or magnetic resonance imaging, cannot definitively distinguish between benign and malignant solid tumors or identify histologic subtype, and early results of molecular imaging studies (positron emission tomography [PET]) in the evaluation of SRMs have not improved on these established modalities. Alternative molecular markers/agents recognizing aberrant cellular pathways of cellular oxidative metabolism, DNA synthesis, and tumor hypoxia tracers are currently under development and investigation for RCC assessment, but to date none are yet clinically applicable or available. In contrast, immuno-PET offers highly selective binding to cancer-specific antigens, and might identify radiographically recognizable and distinct molecular targets. A phase I proof-of-concept study first demonstrated the ability of immuno-PET to discriminate between clear-cell RCC (ccRCC) and non-ccRCC, utilizing a chimeric monoclonal antibody to carbonic anhydrase IX (cG250, girentuximab) labeled with 124I (124I-girentuximab PET); the study examined patients with renal masses who subsequently underwent standard surgical resection. A follow-up phase III multicenter trial confirmed that 124I-cG250-PET can accurately and noninvasively identify ccRCC with high sensitivity (86%), specificity (87%), and positive predictive value (95%). In the challenge to appropriately match treatment of an incidentally identified SRM to its biological potential, this highly accurate and histologically specific molecular imaging modality demonstrates the ability of imaging to provide clinically important preoperative diagnostic information, which can result in optimal and personalized therapy.Keywords: kidney, neoplasms, clear cell, diagnosis, molecular imaging, PET, immuno-PET

Published
2012

7. Measurement of the cosmic ray proton spectrum from 40 GeV to 100 TeV with the DAMPE satellite.

Author

DAMPE Collaboration, An, Q, Asfandiyarov, R, Azzarello, P, Bernardini, P, Bi, XJ, Cai, MS, Chang, J, Chen, DY, Chen, HF, Chen, JL, Chen, W, Cui, MY, Cui, TS, Dai, HT, D'Amone, A, De Benedittis, A, De Mitri, I, Di Santo, M, Ding, M, Dong, TK, Dong, YF, Dong, ZX, Donvito, G, Droz, D, Duan, JL, Duan, KK, D'Urso, D, Fan, RR, Fan, YZ, Fang, F, Feng, CQ, Feng, L, Fusco, P, Gallo, V, Gan, FJ, Gao, M, Gargano, F, Gong, K, Gong, YZ, Guo, DY, Guo, JH, Guo, XL, Han, SX, Hu, YM, Huang, GS, Huang, XY, Huang, YY, Ionica, M, Jiang, W, Jin, X, Kong, J, Lei, SJ, Li, S, Li, WL, Li, X, Li, XQ, Li, Y, Liang, YF, Liang, YM, Liao, NH, Liu, CM, Liu, H, Liu, J, Liu, SB, Liu, WQ, Liu, Y, Loparco, F, Luo, CN, Ma, M, Ma, PX, Ma, SY, Ma, T, Ma, XY, Marsella, G, Mazziotta, MN, Mo, D, Niu, XY, Pan, X, Peng, WX, Peng, XY, Qiao, R, Rao, JN, Salinas, MM, Shang, GZ, Shen, WH, Shen, ZQ, Shen, ZT, Song, JX, Su, H, Su, M, Sun, ZY, Surdo, A, Teng, XJ, Tykhonov, A, Vitillo, S, Wang, C, Wang, H, Wang, HY, and Wang, JZ

Subjects
DAMPE Collaboration, astro-ph.HE
Abstract

The precise measurement of the spectrum of protons, the most abundant component of the cosmic radiation, is necessary to understand the source and acceleration of cosmic rays in the Milky Way. This work reports the measurement of the cosmic ray proton fluxes with kinetic energies from 40 GeV to 100 TeV, with 2 1/2 years of data recorded by the DArk Matter Particle Explorer (DAMPE). This is the first time that an experiment directly measures the cosmic ray protons up to ~100 TeV with high statistics. The measured spectrum confirms the spectral hardening at ~300 GeV found by previous experiments and reveals a softening at ~13.6 TeV, with the spectral index changing from ~2.60 to ~2.85. Our result suggests the existence of a new spectral feature of cosmic rays at energies lower than the so-called knee and sheds new light on the origin of Galactic cosmic rays.

Published
2019

8. Measurement of the cosmic ray proton spectrum from 40 GeV to 100 TeV with the DAMPE satellite

Author

Collaboration, DAMPE, An, Q, Asfandiyarov, R, Azzarello, P, Bernardini, P, Bi, XJ, Cai, MS, Chang, J, Chen, DY, Chen, HF, Chen, JL, Chen, W, Cui, MY, Cui, TS, Dai, HT, D’Amone, A, De Benedittis, A, De Mitri, I, Di Santo, M, Ding, M, Dong, TK, Dong, YF, Dong, ZX, Donvito, G, Droz, D, Duan, JL, Duan, KK, D’Urso, D, Fan, RR, Fan, YZ, Fang, F, Feng, CQ, Feng, L, Fusco, P, Gallo, V, Gan, FJ, Gao, M, Gargano, F, Gong, K, Gong, YZ, Guo, DY, Guo, JH, Guo, XL, Han, SX, Hu, YM, Huang, GS, Huang, XY, Huang, YY, Ionica, M, Jiang, W, Jin, X, Kong, J, Lei, SJ, Li, S, Li, WL, Li, X, Li, XQ, Li, Y, Liang, YF, Liang, YM, Liao, NH, Liu, CM, Liu, H, Liu, J, Liu, SB, Liu, WQ, Liu, Y, Loparco, F, Luo, CN, Ma, M, X., P, Y., S, Ma, T, Y., X, Marsella, G, Mazziotta, MN, Mo, D, Niu, XY, Pan, X, Peng, WX, Peng, XY, Qiao, R, Rao, JN, Salinas, MM, Shang, GZ, Shen, WH, Shen, ZQ, Shen, ZT, Song, JX, Su, H, Su, M, Sun, ZY, Surdo, A, Teng, XJ, Tykhonov, A, Vitillo, S, Wang, C, Wang, H, Wang, HY, and Wang, JZ

Subjects
Nuclear and Plasma Physics, Particle and High Energy Physics, Physical Sciences, DAMPE Collaboration, astro-ph.HE
Abstract

The precise measurement of the spectrum of protons, the most abundant component of the cosmic radiation, is necessary to understand the source and acceleration of cosmic rays in the Milky Way. This work reports the measurement of the cosmic ray proton fluxes with kinetic energies from 40 GeV to 100 TeV, with 2 1/2 years of data recorded by the DArk Matter Particle Explorer (DAMPE). This is the first time that an experiment directly measures the cosmic ray protons up to ~100 TeV with high statistics. The measured spectrum confirms the spectral hardening at ~300 GeV found by previous experiments and reveals a softening at ~13.6 TeV, with the spectral index changing from ~2.60 to ~2.85. Our result suggests the existence of a new spectral feature of cosmic rays at energies lower than the so-called knee and sheds new light on the origin of Galactic cosmic rays.

Published
2019

9. Measurement of the e+e-→π+π-cross section between 600 and 900 MeV using initial state radiation

Author

Ablikim, M, Achasov, MN, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, An, MR, An, Q, Bai, XH, Bai, Y, Bakina, O, Ferroli, RB, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, RA, Cai, H, Cai, X, Calcaterra, A, Cao, GF, Cao, N, Cetin, SA, Chang, JF, Chang, WL, Chelkov, G, Chen, DY, Chen, G, Chen, HS, Chen, ML, Chen, SJ, Chen, XR, Chen, YB, Chen, ZJ, Cheng, WS, Cibinetto, G, Cossio, F, Cui, XF, Dai, HL, Dai, XC, Dbeyssi, A, De Boer, RE, Dedovich, D, Deng, ZY, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, LY, Dong, MY, Dong, X, Du, SX, Fan, YL, Fang, J, Fang, SS, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, CQ, Feng, JH, Fritsch, M, Fu, CD, Gao, Y, Gao, YG, Garzia, I, Liu, Z, Ge, PT, Geng, C, Gersabeck, EM, Gilman, A, Goetzen, K, Gong, L, Gong, WX, Gradl, W, Greco, M, Gu, LM, Gu, MH, Gu, S, Gu, YT, Guan, CY, Guo, AQ, Guo, LB, Guo, RP, Guo, YP, Guskov, A, Han, TT, Han, WY, and Hao, XQ

Subjects
Hadronic cross section, Muon anomaly, Initial state radiation, Pion form factor, BESIII, hep-ex, Nuclear & Particles Physics, Mathematical Physics, Astronomical and Space Sciences, Atomic, Molecular, Nuclear, Particle and Plasma Physics
Abstract

We extract the e+e-→π+π- cross section in the energy range between 600 and 900 MeV, exploiting the method of initial state radiation. A data set with an integrated luminosity of 2.93 fb-1 taken at a center-of-mass energy of 3.773 GeV with the BESIII detector at the BEPCII collider is used. The cross section is measured with a systematic uncertainty of 0.9%. We extract the pion form factor |Fπ|2 as well as the contribution of the measured cross section to the leading-order hadronic vacuum polarization contribution to (g-2)μ. We find this value to be aμππ,LO(600-900MeV)=(368.2±2.5stat±3.3sys)10-10, which is between the corresponding values using the BaBar or KLOE data.

Published
2016

11. Measurements of absolute branching fractions of D-0 -> K-L(0)phi, K-L(0)eta, K-L(0)omega, and K-L(0)eta '

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Gu, S, Yt, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Husken, N, Kl, He, Heinsius, Fh, Heinz, Ch, Held, T, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Gy, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Jing, Mq, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Xy, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Lin, Cx, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Hb, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, S, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Yj, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Poling, R, Prasad, V, Qi, H, Hr, Qi, Kh, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, Dc, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Hf, Shen, Px, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yk, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Wh, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yan, X, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Xq, Yuan, Y, Yuan, Zy, Yue, Cx, Yuncu, A, Zafar, Aa, Zeng, X, Zeng, Y, Zhang, Aq, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jj, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Sl, Zhang, Xd, Zhang, Xy, Zhang, Y, Zhang, Yh, Zhang, Yt, Zhang, Zh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Y, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2022

13. Measurement of A baryon polarization in e(+) e(-) -> Lambda(Lambda)over-bar at root s=3.773 GeV

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Jp, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Egorov, P, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Kk, He, Kl, He, Heinsius, Fh, Heinz, Ch, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Gy, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Husken, N, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Jing, Mq, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Hn, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Li, X, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Limphirat, A, Lin, Cx, Lin, Dx, Lin, T, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Gm, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Plura, S, Pogodin, S, Poling, R, Prasad, V, Qi, H, Hr, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Jj, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Hf, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Stieler, F, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Wh, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, S, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Xh, Wu, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Cj, Xu, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Y, Yuan, Zy, Yue, Cx, Zafar, Aa, Zeng, Xz, Zeng, Y, Zhang, Aq, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Sl, Zhang, Xd, Zhang, Xm, Zhang, Xy, Zhang, Y, Zhang, Yt, Zhang, Yh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2022

14. Search for the decay h(c) -> pi(0) J/psi

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Baldiniferroli, R, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Jp, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Kl, He, Heinsius, Fh, Heinz, Ch, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Gy, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Husken, N, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Jing, Mq, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Hn, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Xy, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Limphirat, A, Lin, Cx, Lin, Dx, Lin, T, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Gm, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Pogodin, S, Poling, R, Prasad, V, Qi, H, Hr, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Jj, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Hf, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Wh, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, S, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Xh, Wu, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Cj, Xu, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Xq, Yuan, Y, Yuan, Zy, Yue, Cx, Zafar, Aa, Zeng, Xz, Zeng, Y, Zhang, Aq, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Sl, Zhang, Xd, Zhang, Xy, Zhang, Y, Zhang, Yt, Zhang, Yh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Subjects
e(+)-e(-) Experiments, Branching fraction, Quarkonium
Published
2022

15. Study of the processes chi(cJ) -> Xi(-)(Xi)over-bar(+) and Xi(0)(Xi)over-bar(0)

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Kl, He, Heinsius, Fh, Heinz, Ch, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Gy, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Husken, N, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Jing, Mq, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Hn, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Xy, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Lin, Cx, Lin, Dx, Lin, T, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Gm, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Pogodin, S, Poling, R, Prasad, V, Qi, H, Hr, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Jj, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Hf, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Wh, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, S, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Xh, Wu, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Cj, Xu, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Xq, Yuan, Y, Yuan, Zy, Yue, Cx, Zafar, Aa, Zeng, X, Zeng, Y, Zhang, Aq, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jj, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Sl, Zhang, Xd, Zhang, Xy, Zhang, Y, Zhang, Yt, Zhang, Yh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Subjects
Branching fraction, e(+)-e(-) Experiments, QCD, Quarkonium
Published
2022

16. Partial wave analysis of J/Psi -> gamma eta 'eta '

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Jp, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Egorov, P, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Kk, He, Kl, He, Heinsius, Fh, Heinz, Ch, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Gy, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Husken, N, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Jing, Mq, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Hn, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Xy, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Limphirat, A, Lin, Cx, Lin, Dx, Lin, T, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Gm, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Plura, S, Pogodin, S, Poling, R, Prasad, V, Qi, H, Hr, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Jj, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Hf, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Stieler, F, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Wh, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, S, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Xh, Wu, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Cj, Xu, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Y, Yuan, Zy, Yue, Cx, Zafar, Aa, Zeng, Xz, Zeng, Y, Zhang, Aq, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Sl, Zhang, Xd, Zhang, Xm, Zhang, Xy, Zhang, Y, Zhang, Yt, Zhang, Yh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2022

17. Study of the h(c)(1(1)P(1)) meson via psi(2S) -> pi(0)h(c) decays at BESIII

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Amoroso, A, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Batozskaya, V, Becker, D, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Cheng, W, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Jp, Dai, Xc, Dbeyssi, A, de Boer, Rb, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Sx, Du, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Fritsch, M, Cd, Fu, Fu, Y, Gao, Xl, Gao, Y, Gao, Yg, Garzia, I, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Gu, S, Yt, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, S, Han, Tt, Han, Tz, Hao, Xq, Harris, Fa, Kl, He, Heinsius, Fh, Held, T, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huesken, N, Hussain, T, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Jiang, Hb, Jiang, Xs, Jiang, Xy, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavezzi, L, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Hb, Li, Hj, Li, Hn, Li, Jl, Li, Jq, Li, Li, K, Lk, Li, Li, L, Pl, Li, Pr, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Zb, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Lz, Libby, J, Limphirat, A, Lin, Cx, Liu, B, Liu, Bj, Liu, Cx, Liu, D, Liu, Dy, Liu, Fh, Liu, F, Liu, Gm, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Ly, Liu, Q, Liu, Sb, Liu, T, Liu, X, Liu, Yb, Liu, Za, Liu, Zq, Long, Yf, Lou, Xc, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lusso, S, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xn, Ma, Xx, Ma, Xy, Ma, Ym, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Yj, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, Y, Papenbrock, M, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Pitka, A, Poling, R, Prasad, V, Qi, H, Qi, M, Ty, Qi, Qian, S, Qiao, Cf, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sarantsev, A, Savrigcu, M, Schelhaas, Y, Schnier, C, Schoenning, K, Shan, W, Shan, Xy, Shao, M, Shen, Cp, Shen, Px, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Sui, Ff, Sun, Gx, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, Yj, Sun, Yk, Sun, Yz, Sun, Zt, Tan, Yx, Tang, Cj, Tang, Gy, Thoren, V, Tsednee, B, Uman, I, Wang, B, Wang, Bl, Wang, Cw, Wang, Dy, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Z, Wang, Zy, Weber, T, Wei, Dh, Weidenkaff, P, Weidner, F, Wen, Hw, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, Z, Xia, L, Xiao, Sy, Xiao, Yj, Xiao, Zj, Xie, Yg, Xie, Yh, Xing, Ty, Xiong, Xa, Gf, Xu, Jj, Xu, Qj, Xu, Xu, W, Xp, Xu, Yan, L, Yan, Wb, Yan, Wc, Yang, Hj, Yang, Hx, Yang, L, Yang, Rx, Yang, Sl, Yang, Yh, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, W, Yuan, Xq, Yuan, Y, Yue, Cx, Zafar, Aa, Zeng, X, Zeng, Y, Zhang, Yh, Zhang, Aq, Zhang, Bl, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, L, Zhang, S, Zhang, Sl, Zhang, Xd, Zhang, Xm, Zhang, Xy, Zhang, Y, Zhang, Yt, Zhang, Zh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Y, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Wj, Zhu, Xl, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2022

18. Observation of the double Dalitz decay eta' -> e(+)e(-)e(+)e(-)

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Amoroso, A, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Bennett, Jv, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Cheng, W, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Jp, Dai, Xc, Dbeyssi, A, de Boer, Rb, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Sx, Du, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Fritsch, M, Cd, Fu, Fu, Y, Gao, Xl, Gao, Y, Gao, Yg, Garzia, I, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Gu, S, Yt, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, S, Han, Tt, Han, Tz, Hao, Xq, Harris, Fa, Kl, He, Heinsius, Fh, Held, T, Heng, Yk, Himmelreich, M, Holtmann, T, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huesken, N, Hussain, T, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Jiang, Hb, Jiang, Xs, Jiang, Xy, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuehn, W, Lane, Jj, Lange, Js, Larin, P, Lavezzi, L, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Hb, Li, Hj, Li, Jl, Li, Jq, Li, Li, K, Lk, Li, Li, L, Pl, Li, Pr, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Zb, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Lz, Libby, J, Lin, Cx, Liu, B, Liu, Bj, Liu, Cx, Liu, D, Liu, Dy, Liu, Fh, Liu, F, Liu, Hb, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Ly, Liu, Q, Liu, Sb, Liu, T, Liu, X, Liu, Yb, Liu, Za, Liu, Zq, Long, Yf, Lou, Xc, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lusso, S, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xn, Ma, Xx, Ma, Xy, Ma, Ym, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Yj, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, Y, Papenbrock, M, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Pitka, A, Poling, R, Prasad, V, Qi, H, Qi, M, Ty, Qi, Qian, S, Qiao, Cf, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sarantsev, A, Savrie, M, Schelhaas, Y, Schnier, C, Schoenning, K, Shan, W, Shan, Xy, Shao, M, Shen, Cp, Shen, Px, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Qq, Song, Yx, Sosio, S, Spataro, S, Sui, Ff, Sun, Gx, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, Yj, Sun, Yk, Sun, Yz, Sun, Zt, Tan, Yx, Tang, Cj, Tang, Gy, Thoren, V, Tsednee, B, Uman, I, Wang, B, Wang, Bl, Wang, Cw, Wang, Dy, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Z, Wang, Zy, Weber, T, Wei, Dh, Weidenkaff, P, Weidner, F, Wen, Hw, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, Z, Xia, L, Xiao, Sy, Xiao, Yj, Xiao, Zj, Xie, Yg, Xie, Yh, Xing, Ty, Xiong, Xa, Gf, Xu, Jj, Xu, Qj, Xu, Xu, W, Xp, Xu, Yan, L, Yan, Wb, Yan, Wc, Yang, Hj, Yang, Hx, Yang, L, Yang, Rx, Yang, Sl, Yang, Yh, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, W, Yuan, Xq, Yuan, Y, Yue, Cx, Yuncu, A, Zafar, Aa, Zeng, Y, Zhang, Bx, Zhang, Gy, Zhang, Hh, Zhang, Hy, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Tj, Zhang, Xy, Zhang, Y, Zhang, Yh, Zhang, Yt, Zhang, Zh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Y, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Wj, Zhu, Xl, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2022

19. Comparative differences in musculoskeletal pain consultation and analgesic prescription for people with dementia

Author

Bullock, DL, Bedson, DJ, Chen, DY, Chew-Graham, CA, and Campbell, P

Subjects
mental disorders, RC
Abstract

Painful musculoskeletal conditions are common in older adults, however pain identification, assessment, and management are reported to be suboptimal for people with dementia. Adequate pain management is an integral aspect of care for people with dementia to prevent or delay negative outcomes, such as behavioural and psychological changes, emergency department attendance, and premature nursing home admission. This study aims to examine musculoskeletal consultations and analgesic prescriptions for people with dementia compared to people without dementia. A dementia cohort (n=36,582) and matched cohort were identified in the Clinical Practice Research Datalink (a UK wide primary care database). Period prevalence for musculoskeletal consultations and analgesic prescriptions were described and logistic regression applied to estimate associations between dementia and musculoskeletal consultation/analgesic prescription from time of dementia diagnosis to 5 years post diagnosis. People with dementia had a consistently (over time) lower prevalence and odds of musculoskeletal consultation and analgesic prescription compared to people without dementia. The evidence suggests that pain management may be suboptimal for people with dementia. These results highlight the need to understand more about practical methods to increase awareness of pain and to employ better methods of pain assessment, evaluation of treatment response and acceptable and effective management for people with dementia, in primary care.

Published
2021

20. Cross section measurement of e(+)e(-) -> p(p)over-bar eta and e(+)e(-) -> p(p)over-bar omega at center-of-mass energies between 3.773 GeV and 4.6 GeV

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Amoroso, A, An, Q, Anita, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Bennett, Jv, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Jp, Dai, Xc, Dbeyssi, A, de Boer, Rb, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Sx, Du, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Fritsch, M, Cd, Fu, Fu, Y, Gao, Xl, Gao, Y, Gao, Yg, Garzia, I, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Gu, S, Yt, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, S, Han, Tt, Han, Tz, Hao, Xq, Harris, Fa, Kl, He, Heinsius, Fh, Held, T, Heng, Yk, Himmelreich, M, Holtmann, T, Hou, Yr, Hou, Zl, Hm, Hu, Jf, Hu, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Huesken, N, Hussain, T, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Jiang, Hb, Jiang, Xs, Jiang, Xy, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavezzi, L, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Hb, Li, Hj, Li, Jl, Li, Jq, Li, Li, K, Lk, Li, Li, L, Pl, Li, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Zb, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Lz, Libby, J, Lin, Cx, Liu, B, Liu, Bj, Liu, Cx, Liu, D, Liu, Dy, Liu, Fh, Liu, F, Liu, Hb, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Q, Liu, Sb, Liu, S, Liu, T, Liu, X, Liu, Yb, Liu, Za, Liu, Zq, Long, Yf, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lusso, S, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xn, Ma, Xx, Ma, Xy, Ma, Ym, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Yj, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Pitka, A, Poling, R, Prasad, V, Qi, H, Hr, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Shan, Dc, Shan, W, Shan, Xy, Shao, M, Shen, Cp, Shen, Px, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Qq, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Sui, Ff, Sun, Gx, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yk, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Thoren, V, Tsednee, B, Uman, I, Wang, B, Wang, Bl, Wang, Cw, Wang, Dy, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Z, Wang, Zy, Wei, Dh, Weidenkaff, P, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Yj, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Xiong, Xa, Gf, Xu, Jj, Xu, Qj, Xu, Xu, W, Xp, Xu, Yan, L, Yan, Wb, Yan, Wc, Yan, X, Yang, Hj, Yang, Hx, Yang, L, Yang, Rx, Yang, Sl, Yang, Yh, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, W, Yuan, Xq, Yuan, Y, Yuan, Zy, Yue, Cx, Yuncu, A, Zafar, Aa, Zeng, Y, Zhang, Bx, Zhang, Gy, Zhang, Hh, Zhang, Hy, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Tj, Zhang, Xy, Zhang, Y, Zhang, Yh, Zhang, Yt, Zhang, Zh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Y, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Wj, Zhu, Xl, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2021

21. Determination of the Lambda(c)+ spin via the reaction e(+)e(-) -> Lambda(c)(Lambda)over-bar(c)

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Ferroli, Rb, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Gu, S, Yt, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Kl, He, Heinsius, Fh, Heinz, Ch, Held, T, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Gy, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Husken, N, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Jing, Mq, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Xy, Li, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Lin, Cx, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Hb, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, S, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Yj, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Poling, R, Prasad, V, Qi, H, Hr, Qi, Kh, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, Dc, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Hf, Shen, Px, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yk, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Wh, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yan, X, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Yf, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Xq, Yuan, Y, Yuan, Zy, Yue, Cx, Yuncu, A, Zafar, Aa, Zeng, Zeng, Y, Zhang, Aq, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jj, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Sl, Zhang, Xd, Zhang, Xy, Zhang, Y, Zhang, Yh, Zhang, Yt, Zhang, Zh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Y, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Published
2021

22. Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies

Author

Chen, DY, Sawamura, T, Dixon, RAF, Sanchez-Quesada, JL, and Chen, CH

Subjects
electronegative LDL, atherosclerotic cardiovascular disease (ASCVD), autoimmune rheumatic diseases (AIRDs), interleukin 1&#946, L5, (IL-1&#946, lipids (amino acids, peptides, and proteins), lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1), )
Abstract

Atherosclerosis has been linked with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Autoimmune rheumatic diseases (AIRDs) are associated with accelerated atherosclerosis and ASCVD. However, the mechanisms underlying the high ASCVD burden in patients with AIRDs cannot be explained only by conventional risk factors despite disease-specific factors and chronic inflammation. Nevertheless, the normal levels of plasma low-density lipoprotein (LDL) cholesterol observed in most patients with AIRDs do not exclude the possibility of increased LDL atherogenicity. By using anion-exchange chromatography, human LDL can be divided into five increasingly electronegative subfractions, L1 to L5, or into electropositive and electronegative counterparts, LDL (+) and LDL (-). Electronegative L5 and LDL (-) have similar chemical compositions and can induce adverse inflammatory reactions in vascular cells. Notably, the percentage of L5 or LDL (-) in total LDL is increased in normolipidemic patients with AIRDs. Electronegative L5 and LDL (-) are not recognized by the normal LDL receptor but instead signal through the lectin-like oxidized LDL receptor 1 (LOX-1) to activate inflammasomes involving interleukin 1 beta (IL-1 beta). Here, we describe the detailed mechanisms of AIRD-related ASCVD mediated by L5 or LDL (-) and discuss the potential targeting of LOX-1 or IL-1 beta signaling as new therapeutic modalities for these diseases.

Published
2021

23. Measurement of the D -> K-pi(+)pi(+)pi(-) and D -> K-pi(+)pi(0) coherence factors and average strong-phase differences in quantum-correlated D(D)over-bar decays

Author

Ablikim, M, Achasov, Mn, Adlarson, P, Ahmed, S, Albrecht, M, Aliberti, R, Amoroso, A, Mr, An, An, Q, Bai, Xh, Bai, Y, Bakina, O, Baldini Ferroli, R, Balossino, I, Ban, Y, Begzsuren, K, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Bloms, J, Bortone, A, Boyko, I, Briere, Ra, Cai, H, Cai, X, Calcaterra, A, Cao, Gf, Cao, N, Cetin, Sa, Chang, Jf, Chang, Wl, Chelkov, G, Chen, Dy, Chen, G, Chen, Hs, Chen, Ml, Chen, Sj, Chen, Xr, Chen, Yb, Chen, Zj, Cheng, Ws, Cibinetto, G, Cossio, F, Cui, Xf, Dai, Hl, Dai, Xc, Dbeyssi, A, de Boer, Re, Dedovich, D, Deng, Zy, Denig, A, Denysenko, I, Destefanis, M, De Mori, F, Ding, Y, Dong, C, Dong, J, Dong, Ly, Dong, My, Dong, X, Sx, Du, Fan, Yl, Fang, J, Fang, Ss, Fang, Y, Farinelli, R, Fava, L, Feldbauer, F, Felici, G, Feng, Cq, Feng, Jh, Fritsch, M, Cd, Fu, Gao, Y, Gao, Yg, Garzia, I, Pt, Ge, Geng, C, Gersabeck, Em, Gilman, A, Goetzen, K, Gong, L, Gong, Wx, Gradl, W, Greco, M, Lm, Gu, Mh, Gu, Gu, S, Yt, Gu, Guan, Cy, Guo, Aq, Guo, Lb, Guo, Rp, Guo, Yp, Guskov, A, Han, Tt, Han, Wy, Hao, Xq, Harris, Fa, Husken, N, Kl, He, Heinsius, Fh, Heinz, Ch, Held, T, Heng, Yk, Herold, C, Himmelreich, M, Holtmann, T, Hou, Yr, Hou, Zl, Hm, Hu, Hu, Jifeng, Hu, T, Hu, Y, Huang, Gs, Huang, Lq, Huang, Xt, Huang, Yp, Huang, Z, Hussain, T, Andersson, Wi, Imoehl, W, Irshad, M, Jaeger, S, Janchiv, S, Ji, Q, Qp, Ji, Xb, Ji, Xl, Ji, Yy, Ji, Jiang, Hb, Jiang, Xs, Jiao, Jb, Jiao, Z, Jin, S, Jin, Y, Johansson, T, Kalantar-Nayestanaki, N, Kang, Xs, Kappert, R, Kavatsyuk, M, Bc, Ke, Keshk, Ik, Khoukaz, A, Kiese, P, Kiuchi, R, Kliemt, R, Koch, L, Kolcu, Ob, Kopf, B, Kuemmel, M, Kuessner, M, Kupsc, A, Kurth, Mg, Kuhn, W, Lane, Jj, Lange, Js, Larin, P, Lavania, A, Lavezzi, L, Lei, Zh, Leithoff, H, Lellmann, M, Lenz, T, Li, C, Ch, Li, Dm, Li, Li, F, Li, G, Li, H, Hb, Li, Hj, Li, Jl, Li, Jq, Li, Js, Li, Li, K, Lk, Li, Li, L, Pr, Li, Sy, Li, Wd, Li, Wg, Li, Xh, Li, Xl, Li, Li, X, Zy, Li, Liang, H, Liang, Yf, Liang, Yt, Liao, Gr, Liao, Lz, Libby, J, Lin, Cx, Liu, Bj, Liu, Cx, Liu, D, Liu, Fh, Liu, F, Liu, Hb, Liu, Hm, Liu, Hh, Liu, Jb, Liu, Jl, Liu, Jy, Liu, K, Liu, Ky, Liu, L, Liu, Mh, Liu, Pl, Liu, Q, Liu, Sb, Liu, S, Liu, T, Liu, Wm, Liu, X, Liu, Y, Liu, Yb, Liu, Za, Liu, Zq, Lou, Xc, Fx, Lu, Hj, Lu, Jd, Lu, Jg, Lu, Xl, Lu, Lu, Y, Yp, Lu, Luo, Cl, Luo, Mx, Luo, Pw, Luo, T, Luo, Xl, Lusso, S, Lyu, Xr, Fc, Ma, Hl, Ma, Ll, Ma, Mm, Ma, Qm, Ma, Rq, Ma, Rt, Ma, Xx, Ma, Xy, Ma, Maas, Fe, Maggiora, M, Maldaner, S, Malde, S, Malik, Qa, Mangoni, A, Mao, Yj, Mao, Zp, Marcello, S, Meng, Zx, Messchendorp, Jg, Mezzadri, G, Min, Tj, Mitchell, Re, Xh, Mo, Yj, Mo, Muchnoi, Ny, Muramatsu, H, Nakhoul, S, Nefedov, Y, Nerling, F, Nikolaev, Ib, Ning, Z, Nisar, S, Olsen, Sl, Ouyang, Q, Pacetti, S, Pan, X, Pan, Y, Pathak, A, Patteri, P, Pelizaeus, M, Peng, Hp, Peters, K, Pettersson, J, Ping, Jl, Ping, Rg, Poling, R, Prasad, V, Qi, H, Hr, Qi, Kh, Qi, Qi, M, Ty, Qi, Qian, S, Qian, Wb, Qian, Z, Qiao, Cf, Qin, Lq, Qin, Xp, Qin, Xs, Qin, Zh, Qiu, Jf, Sq, Qu, Rashid, Kh, Ravindran, K, Redmer, Cf, Rivetti, A, Rodin, V, Rolo, M, Rong, G, Rosner, C, Rump, M, Sang, Hs, Sarantsev, A, Schelhaas, Y, Schnier, C, Schoenning, K, Scodeggio, M, Shan, Dc, Shan, W, Shan, Xy, Shangguan, Jf, Shao, M, Shen, Cp, Shen, Px, Shen, Xy, Shi, Hc, Shi, Rs, Shi, X, Shi, Xd, Song, Jj, Song, Wm, Song, Yx, Sosio, S, Spataro, S, Kx, Su, Pp, Su, Sui, Ff, Sun, Gx, Sun, Hk, Sun, Jf, Sun, L, Sun, Ss, Sun, T, Sun, Wy, Sun, X, Sun, Yj, Sun, Yk, Sun, Yz, Sun, Zt, Tan, Yh, Tan, Yx, Tang, Cj, Tang, Gy, Tang, J, Teng, Jx, Thoren, V, Tian, Yt, Uman, I, Wang, B, Wang, Cw, Wang, Dy, Wang, Hj, Wang, Hp, Wang, K, Wang, Ll, Wang, M, Wang, Mz, Wang, W, Wang, Wh, Wang, Wp, Wang, X, Wang, Xf, Wang, Xl, Wang, Y, Wang, Yd, Wang, Yf, Wang, Yq, Wang, Yy, Wang, Z, Wang, Zy, Wei, Dh, Weidenkaff, P, Weidner, F, Wen, Sp, White, Dj, Wiedner, U, Wilkinson, G, Wolke, M, Wollenberg, L, Jf, Wu, Lh, Wu, Lj, Wu, Wu, X, Wu, Z, Xia, L, Xiao, H, Xiao, Sy, Xiao, Zj, Xie, Xh, Xie, Yg, Xie, Yh, Xing, Ty, Gf, Xu, Qj, Xu, Xu, W, Xp, Xu, Yc, Xu, Yan, F, Yan, L, Yan, Wb, Yan, Wc, Yan, X, Yang, Hj, Yang, Hx, Yang, L, Yang, Sl, Yang, Yx, Yang, Y, Yang, Z, Ye, M, Mh, Ye, Yin, Jh, You, Zy, Bx, Yu, Cx, Yu, Yu, G, Js, Yu, Yu, T, Yuan, Cz, Yuan, L, Yuan, Xq, Yuan, Y, Yuan, Zy, Yue, Cx, Yuncu, A, Zafar, Aa, Zeng, Y, Zhang, Bx, Zhang, Gy, Zhang, H, Zhang, Hh, Zhang, Hy, Zhang, Jj, Zhang, Jl, Zhang, Jq, Zhang, Jw, Zhang, Jy, Zhang, Jz, Zhang, J, Zhang, Lm, Zhang, Lq, Zhang, L, Zhang, S, Zhang, Sf, Zhang, Xd, Zhang, Xy, Zhang, Y, Zhang, Yh, Zhang, Yt, Zhang, Zh, Zhang, Zy, Zhao, G, Zhao, J, Zhao, Jy, Zhao, Jz, Zhao, L, Zhao, Mg, Zhao, Q, Zhao, Sj, Zhao, Yb, Zhao, Yx, Zhao, Zg, Zhemchugov, A, Zheng, B, Zheng, Jp, Zheng, Y, Zheng, Yh, Zhong, B, Zhong, C, Zhou, Lp, Zhou, Q, Zhou, X, Zhou, Xk, Zhou, Xr, Zhou, Xy, Zhu, An, Zhu, J, Zhu, K, Zhu, Kj, Zhu, Sh, Zhu, Tj, Zhu, Wj, Zhu, Yc, Zhu, Za, Zou, Bs, and Zou, Jh

Subjects
e(+)-e(-) Experiments, CKM angle gamma, Charm physics
Published
2021

24. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B

Author

Gane, EJ, Kim, HJ, Visvanathan, K, Kim, YJ, Anh-Hoa, N, Wallin, JJ, Chen, DY, McDonald, C, Arora, P, Tan, SK, Gaggar, A, Roberts, SK, Lim, Y-S, Gane, EJ, Kim, HJ, Visvanathan, K, Kim, YJ, Anh-Hoa, N, Wallin, JJ, Chen, DY, McDonald, C, Arora, P, Tan, SK, Gaggar, A, Roberts, SK, and Lim, Y-S

Abstract

BACKGROUND AND AIMS: In patients with chronic hepatitis B (CHB) infection, activation of toll-like receptor 8 may induce antiviral immunity and drive functional cure. Selgantolimod, a toll-like receptor 8 agonist, was evaluated in patients with CHB who were virally suppressed on oral antiviral treatment or viremic and not on oral antiviral treatment. APPROACH AND RESULTS: In this phase 1b study, patients were randomized 4:1 to receive either selgantolimod or placebo once weekly. Virally suppressed patients received either 1.5 mg (for 2 weeks) or 3 mg (for 2 weeks or 4 weeks). Viremic patients received 3 mg for 2 weeks. The primary endpoint was safety, as assessed by adverse events (AEs), laboratory abnormalities, and vital sign examination. Pharmacokinetic and pharmacodynamic parameters were assessed by plasma analysis. A total of 38 patients (28 virally suppressed, 10 viremic) were enrolled from six sites in Australia, New Zealand, and South Korea. Twenty patients (53%) experienced an AE and 32 (84%) had laboratory abnormalities, all of which were mild or moderate in severity. The most common AEs were headache (32%), nausea (24%), and dizziness (13%). With a half-life of 5 hours, no accumulation of selgantolimod was observed with multiple dosing. Selgantolimod induced transient dose-dependent increases in serum cytokines, including IL-12p40 and IL-1RA, which are important for the expansion and activity of multiple T- cell subsets and innate immunity. CONCLUSION: Selgantolimod was safe and well-tolerated in virally suppressed and viremic patients with CHB and elicited cytokine responses consistent with target engagement. Further studies with longer durations of selgantolimod treatment are required to evaluate efficacy.

Published
2021

25. Partial wave analysis of psi(3686) -> K+ K- eta

Author

Ablikim, M, Achasov, MN, Adlarson, P, Ahmed, S, Albrecht, M, Alekseev, M, Amoroso, A, An, FF, An, Q, Bai, Y, Bakina, O, Ferroli, RB, Balossino, I, Ban, Y, Begzsuren, K, Bennett, JV, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Boyko, I, Briere, RA, Cai, H, Cai, X, Calcaterra, A, Cao, GF, Cao, N, Cetin, SA, Chai, J, Chang, JF, Chang, WL, Chelkov, G, Chen, DY, Chen, G, Chen, HS, Chen, JC, Chen, ML, Chen, SJ, Chen, YB, Cheng, W, Cibinetto, G, Cossio, F, Cui, XF, Dai, HL, Dai, JP, Dai, XC, Dbeyssi, A, and Collaboration, BESIII

Abstract

Using a sample of (448.1±2.9)×106 ψ(3686) events collected with the BESIII detector, we perform the first partial wave analysis of ψ(3686)→K+K-η. In addition to the well established states, φ(1020), φ(1680), and K3∗(1780), contributions from X(1750), ρ(2150), ρ3(2250), and K2∗(1980) are also observed. The X(1750) state is determined to be a 1-resonance. The simultaneous observation of the φ(1680) and X(1750) indicates that the X(1750), with previous observations in photoproduction, is distinct from the φ(1680). The masses, widths, branching fractions of ψ(3686)→K+K-η, and the intermediate resonances are also measured.

Published
2020

26. Search for the rare decay eta ' -> pi(0)pi(0)pi(0)pi(0) at BESIII

Author

Ablikim, M, Achasov, MN, Adlarson, P, Ahmed, S, Albrecht, M, Alekseev, M, Amoroso, A, An, Q, Anita, YB, Bakina, O, Ferroli, RB, Balossino, I, Ban, Y, Begzsuren, K, Bennett, JV, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Boyko, I, Briere, RA, Cai, H, Cai, X, Calcaterra, A, Cao, GF, Cao, N, Cetin, SA, Chai, J, Chang, JF, Chang, WL, Chelkov, G, Chen, DY, Chen, G, Chen, HS, Chen, J, Chen, ML, Chen, SJ, Chen, XR, Chen, YB, Cheng, W, Cibinetto, G, Cossio, F, Cui, XF, Dai, HL, Dai, JP, Dai, XC, Dbeyssi, A, Elbert, B, and Collaboration, BESIII

Abstract

Using a sample of 1.31×109 J/ψ events collected with the BESIII detector, we perform a search for the rare decay η′→4π0 via J/ψ→γη′. No significant η′ signal is observed in the 4π0 invariant mass spectrum. With a Bayesian approach, the upper limit on the branching fraction is determined to be B(η′→4π0)

Published
2020

27. Search for baryon and lepton number violating decays D+ -> (Lambda)over-bar((Sigma)over-bar(0))e(+) and D+ -> Lambda(Sigma(0))e(+)

Author

Ablikim, M, Achasov, MN, Adlarson, P, Ahmed, S, Albrecht, M, Alekseev, M, Amoroso, A, An, FF, An, Q, Bai, Y, Bakina, O, Ferroli, RB, Ban, Y, Begzsuren, K, Bennett, JV, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Boyko, I, Briere, RA, Cai, H, Cai, X, Calcaterra, A, Cao, GF, Cao, N, Cetin, SA, Chai, J, Chang, JF, Chang, WL, Chelkov, G, Chen, DY, Chen, G, Chen, HS, Chen, JC, Chen, ML, Shen, SJ, Chen, YB, Cheng, W, Cibinetto, G, Cossio, F, Cui, XF, Dai, HL, Dai, JP, Dai, XC, Dbeyssi, A, Dedovich, D, and Collaboration, BESIII

Abstract

Using a 2.93 fb − 1 data sample of electron-positron collisions taken with the BESIII detector at a center-of-mass energy of 3.773 GeV, which corresponds to ( 8296 ± 31 ± 64 ) × 10 3 D + D − pairs, we search for the baryon and lepton number violating decays D + → ¯ Λ ( ¯ Σ 0 ) e + and D + → Λ ( Σ 0 ) e + . No obvious signals are found with the current statistics and upper limits on the branching fractions of these four decays are set at the level of 10 − 6 at 90% confidence level.

Published
2020

28. Observation of the decays chi(cJ) -> phi phi eta

Author

Ablikim, M, Achasov, MN, Adlarson, P, Ahmed, S, Albrecht, M, Alekseev, M, Amoroso, A, An, FF, An, Q, Bai, Y, Bakina, O, Ferroli, RB, Balossino, I, Ban, Y, Begzsuren, K, Bennett, JV, Berger, N, Bertani, M, Bettoni, D, Bianchi, F, Biernat, J, Bloms, J, Boyko, I, Briere, RA, Cai, H, Cai, X, Calcaterra, A, Cao, GF, Cao, N, Cetin, SA, Chai, J, Chang, JF, Chang, WL, Chelkov, G, Chen, DY, Chen, G, Chen, HS, Chen, J, Chen, ML, Chen, SJ, Chen, XR, Chen, YB, Cheng, W, Cibinetto, G, Cossio, F, Cui, XF, Dai, HL, Dai, JP, Dai, XC, and Collaboration, BESIII

Abstract

Using a data sample of (448.1±2.9)×106 ψ(3686) decays collected by the BESIII detector at the Beijing Electron Positron Collider (BEPCII), we observe the decays χcJ→φφη(J=0,1,2), where the χcJ are produced via the radiative processes ψ(3686)→γχcJ. The branching fractions are measured to be B(χc0→φφη)=(8.41±0.74±0.62)×10-4, B(χc1→φφη)=(2.96±0.43±0.22)×10-4, and B(χc2→φφη)=(5.33±0.52±0.39)×10-4, where the first uncertainties are statistical, and the second are systematic. We also search for intermediate states in the φφ or ηφ subsystems, but no significant structure is seen due to the limited statistics.

Published
2020

29. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Author

Ravaud, A, Motzer, Rj, Pandha, Hs, George, Dj, Pantuck, Aj, Patel, A, Chang, Yh, Escudier, B, Donskov, F, Magheli, A, Carteni, G, Laguerre, B, Tomczak, P, Breza, J, Gerletti, P, Lechuga, M1, Lin, X, Martini, Jf, Ramaswamy, K, Casey, M, Staehler, M, Patard, Jj, Gruenwald, V, Link, K, Doehn, C, Heinzer, H, Grimm, M-O, Wirth, M, Stoeckle, M, Heidenreich, A, Garcia del Muro Solans, X, Mellado, Bo, Castellano, Dg, Frydenberg, M, Schobinger, Sr, Dimopoulos, Ma, Rothermundt, C, Climent Duran MA, Melotti, B, Procopio, G, Boccardo, F, Sella, A, Stewart, S, Adenis, A, Jones, Rj, Chevreau, C, Prausova, J, Vyzula, R, Oudard, S, Jacqmin, D, Gravis, G, Varela, R, Herrmann, E, Lim, Hy, Lee, J-L, Kim, Yh, Kim, Jh, Y-C, Ou, Papakotoulas, P, Iacobelli, S, Chowdhury, S, Passalacqua, R, Tomasek, J, Anton Aparicio LM, Linassier, C, Hauser, S, Bergmann, L, Hawkins, Re, Szczylik, C, Zdrojowy, R, Sosnowski, M, Koralewski, P, Wiechnio, Pj, Schraml, J, Mardiak, J, Laurinc, P, Kliment, J, Rosenbaum, E, Lundstam, S, Flodgren, P, Ljungberg, B, Stenzl, A, Schnoeller, Tj, Mcdermott, Sr, Breathnach, Os, Mccaffrey, Ja, Donnellan, P, The, G-C, Rolland, F, Brekkan, E, Nilsson, C, Kim, Wy, Bishoff, J, Chung, J, Shore, Nd, Master, V, Tang Chen DY, Ye, D, Huang, Y, Jin, J, Song, B, Zhou, F, Galceran, Jc, Yao, X, and Zhang, X.

Subjects
Male, Indoles, medicine.medical_treatment, Clinical Trial, Phase III, 030232 urology & nephrology, Nephrectomy, 0302 clinical medicine, Renal cell carcinoma, Clinical endpoint, 80 and over, Adjuvant, Aged, 80 and over, Adolescent, Adult, Aged, Antineoplastic Agents, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Double-Blind Method, Drug Administration Schedule, Female, Humans, Kidney Neoplasms, Middle Aged, Pyrroles, Survival Analysis, Young Adult, Medicine (all), Sunitinib, General Medicine, Multicenter Study, 030220 oncology & carcinogenesis, Randomized Controlled Trial, medicine.drug, medicine.medical_specialty, Urology, Placebo, 03 medical and health sciences, Journal Article, Carcinoma, medicine, Chemotherapy, Survival analysis, business.industry, Renal Cell, medicine.disease, Surgery, Clinical trial, business
Abstract

BACKGROUNDSunitinib, a vascular endothelial growth factor pathway inhibitor, is an effectivetreatment for metastatic renal-cell carcinoma. We sought to determine the efficacyand safety of sunitinib in patients with locoregional renal-cell carcinoma athigh risk for tumor recurrence after nephrectomy.METHODSIn this randomized, double-blind, phase 3 trial, we assigned 615 patients withlocoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib(50 mg per day) or placebo on a 4-weeks-on, 2-weeks-off schedule for 1 year oruntil disease recurrence, unacceptable toxicity, or consent withdrawal. The primaryend point was disease-free survival, according to blinded independent central review.Secondary end points included investigator-assessed disease-free survival,overall survival, and safety.RESULTSThe median duration of disease-free survival was 6.8 years (95% confidence interval[CI], 5.8 to not reached) in the sunitinib group and 5.6 years (95% CI, 3.8 to6.6) in the placebo group (hazard ratio, 0.76; 95% CI, 0.59 to 0.98; P=0.03). Overallsurvival data were not mature at the time of data cutoff. Dose reductions becauseof adverse events were more frequent in the sunitinib group than in theplacebo group (34.3% vs. 2%), as were dose interruptions (46.4% vs. 13.2%) anddiscontinuations (28.1% vs. 5.6%). Grade 3 or 4 adverse events were more frequentin the sunitinib group (48.4% for grade 3 events and 12.1% for grade 4 events)than in the placebo group (15.8% and 3.6%, respectively). There was a similarincidence of serious adverse events in the two groups (21.9% for sunitinib vs.17.1% for placebo); no deaths were attributed to toxic effects.CONCLUSIONSAmong patients with locoregional clear-cell renal-cell carcinoma at high risk fortumor recurrence after nephrectomy, the median duration of disease-free survivalwas significantly longer in the sunitinib group than in the placebo group, at a costof a higher rate of toxic events. (Funded by Pfizer; S-TRAC ClinicalTrials.gov number,NCT00375674.)

Published
2016

30. Spinal Cord Injury Blunted Effects of Endothelin-1 on Ca2+ Transients and Calcium Current in Isolated Rat Cardiomyocytes

Author

Gou Sh, Yuan Wj, Yuan W, Chen Y, Jia Ls, Chen Dy, Liu Y, Yong-fei Guo, and Ren Aj

Subjects
Male, Inotrope, medicine.medical_specialty, Patch-Clamp Techniques, Contraction (grammar), Calcium Channels, L-Type, Physiology, chemistry.chemical_element, Calcium, Calcium current, Rats, Sprague-Dawley, Internal medicine, medicine, Animals, Myocyte, Myocytes, Cardiac, Patch clamp, Spinal cord injury, Spinal Cord Injuries, Dose-Response Relationship, Drug, Endothelin-1, Chemistry, General Medicine, medicine.disease, Myocardial Contraction, Endothelin 1, Rats, Endocrinology, Anesthesia
Abstract

Plasma endothelin-1 (ET-1) levels are elevated in spinal cord injury (SCI), and ET-1 may be involved in the pathophysiology of this condition. However, its effects on contractile function of the heart of SCI rats are still unknown. To define more clearly the possiblel role of ET-1 following SCI, we investigated the effect of ET-1 on the contraction, calcium transients and L-type calcium current (ICa,L) in the cardiomyocytes of control and SCI rats. Sixteen Sprague-Dawley male rats aged 80-100 days and weighing 250-350 g were randomized into control and SCI groups. Fourteen days following compression injury to the spinal cord, effects of ET-1 on the contraction, calcium transients and ICa,L were studied in the cardiomyocytes of control and SCI rats by the technique of simultaneous measurement of intracellular Ca2+ and contraction and by whole-cell configuration of the patch-clamp technique. In myocytes from control rats, ET-1 significantly increased contraction, the magnitude of Ca2+ transients and the peak amplitude of ICa,L. However, ET-1 had little effect on the amplitude of contraction, calcium transients and ICa,L in myocytes from SCI rats. These results suggest that the positive inotropic effects of ET-1 on control myocardial contraction may be altered in pathological states such as SCI.

Published
2010

31. The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell Proliferation

Author

Hong Zhou, Shu Mang Feng, Ruth Chen Dy, Laura S. Caskey, Debra Hunter, Xihui Yang, H. Shelton Earp, Rebecca S. Muraoka-Cook, and Carolyn I. Sartor

Subjects
Cytoplasm, Receptor, ErbB-4, animal structures, medicine.drug_class, Neuregulin-1, Article, Tyrosine-kinase inhibitor, chemistry.chemical_compound, Endocrinology, Epidermal growth factor, Cell Line, Tumor, medicine, Humans, Tyrosine, Mammary Glands, Human, Molecular Biology, Cell Proliferation, biology, Cell growth, fungi, Tyrosine phosphorylation, General Medicine, Molecular biology, Growth Inhibitors, Peptide Fragments, Protein Structure, Tertiary, ErbB Receptors, chemistry, biology.protein, Phosphorylation, Female, GRB2, Amyloid Precursor Protein Secretases, Tyrosine kinase
Abstract

Unlike the proliferative action of other epidermal growth factor (EGF) receptor family members, HER4/ErbB4 is often associated with growth-inhibitory and differentiation signaling. These actions may involve HER4 two-step proteolytic processing by intramembraneous gamma-secretase, releasing the soluble, intracellular 80-kDa HER4 cytoplasmic domain, s80HER4. We demonstrate that pharmacological inhibition of either gamma-secretase activity or HER4 tyrosine kinase activity blocked heregulin-dependent growth inhibition of SUM44 breast cancer cells. We next generated breast cell lines stably expressing GFP-s80HER4 [green fluorescent protein (GFP) fused to the N terminus of the HER4 cytoplasmic domain, residues 676-1308], GFP-CT(HER4) (GFP fused to N terminus of the HER4 C-terminus distal to the tyrosine kinase domain, residues 989-1308), or GFP alone. Both GFP-s80HER4 and GFP-CTHER4 were found in the nucleus, but GFP-s80HER4 accumulated to a greater extent and sustained its nuclear localization. s80HER4 was constitutively tyrosine phosphorylated, and treatment of cells with a specific HER family tyrosine kinase inhibitor 1) blocked tyrosine phosphorylation; 2) markedly diminished GFP-s80HER4 nuclear localization; and 3) reduced signal transducer and activator of transcription (STAT)5A tyrosine phosphorylation and nuclear localization as well as GFP-s80HER4:STAT5A interaction. Multiple normal mammary and breast cancer cell lines, stably expressing GFP-s80HER4 (SUM44, MDA-MB-453, MCF10A, SUM102, and HC11) were growth inhibited compared with the same cell line expressing GFP-CTHER4 or GFP alone. The s80HER4-induced cell number reduction was due to slower growth because rates of apoptosis were equivalent in GFP-, GFP-CTHER4-, and GFP-s80HER4-expressing cells. Lastly, GFP-s80HER4 enhanced differentiation signaling as indicated by increased basal and prolactin-dependent beta-casein expression. These results indicate that surface HER4 tyrosine phosphorylation and ligand-dependent release of s80HER4 are necessary, and s80HER4 signaling is sufficient for HER4-dependent growth inhibition.

Published
2007

32. Cloning, expression and functional analysis of MAP30 from Momordica charantia reveals its induction of apoptosis of the BGC-823 cells

Author

Han, XH, Xue, YJ, Chen, DY, Shao, SH, Huang, H, Li, XQ, and Xu, HX

Subjects
Momordica charantia, MAP30, BGC-823 cells, apoptosis, mitochondria membrane potential, Cyt C, caspase-9, Apaf-1, caspase-3
Abstract

Momordica Anti-HIV Protein 30 (MAP30) can induce many tumour cells apoptosis, but the mechanism is still unclear. Since the content of MAP30 in Momordica charantia is limited, in this study, the MAP30 gene was cloned and expressed and the induction of the recombinant MAP30 protein on the apoptosis of BGC-823 cells was investigated. Morphological changes were observed by microscopy. The normal, apoptotic and necrotic cells were identified by fluorescence staining. The apoptosis percentage and the mitochondria membrane potential level was displayed by flow cytometry analysis and JC-1 fluorescent probe assay, respectively. The mRNA expression of caspase-9 and Apaf-1 was investigated by reverse transcription polymerase chain reaction (RT-PCR). The content of Cyt C and the activity of Caspase-3 were investigated by ELISA and spectrophotometric method, respectively. In this study, the MAP30 gene was expressed and the recombinant MAP30 protein was purified successfully. The results of morphology, the fluorescence staining and the flow cytometry analysis indicated that MAP30 could induce cells apoptosis. When treated with MAP30, the mitochondria membrane potential level decreased, while the expression of caspase-9 and Apaf-1 mRNA, the Cyt C content, and the caspase-3 activity all increased. All these indicated that the recombinant MAP30 protein could induce the BGC-823 cells apoptosis in vitro via the mitochondrial pathway.Key words: Momordica charantia, MAP30, BGC-823 cells, apoptosis, mitochondria membrane potential, Cyt C, caspase-9, Apaf-1, caspase-3.

Published
2013

33. Activation of a Novel Calcium-dependent Protein-tyrosine Kinase

Author

Benjamin F. Calvo, Xiong Li, Matthias Wilm, Robert J. Anderegg, Lee M. Graves, Ruth Chen Dy, Deborah Hunter, H. Shelton Earp, Hong Yu, Thomas L. Dawson, and Gail S. Marchetto

Subjects
MAP kinase kinase kinase, biology, Cyclin-dependent kinase 2, Tyrosine phosphorylation, Cell Biology, Mitogen-activated protein kinase kinase, Biochemistry, Molecular biology, Protein kinase R, MAP2K7, Cell biology, chemistry.chemical_compound, chemistry, biology.protein, ASK1, Cyclin-dependent kinase 9, Molecular Biology
Abstract

Many G protein-coupled receptors (e.g. that of angiotensin II) activate phospholipase Cβ, initially increasing intracellular calcium and activating protein kinase C. In the WB and GN4 rat liver epithelial cell lines, agonist-induced calcium signals also stimulate tyrosine phosphorylation and subsequently increase the activity of c-Jun N-terminal kinase (JNK). We have now purified the major calcium-dependent tyrosine kinase (CADTK), and by peptide and nucleic acid sequencing identified it as a rat homologue of human PYK2. CADTK/PYK2 is most closely related to p125FAK and both enzymes are expressed in WB and GN4 cells. Angiotensin II, which only slightly increases p125FAK tyrosine phosphorylation in GN4 cells, substantially increased CADTK tyrosine autophosphorylation and kinase activity. Agonists for other G protein-coupled receptors (e.g. LPA), or those increasing intracellular calcium (thapsigargin), also stimulated CADTK. In comparing the two rat liver cell lines, GN4 cells exhibited ∼ 5-fold greater angiotensin II- and thapsigargin-dependent CADTK activation than WB cells. Although maximal JNK activation by stress-dependent pathways (e.g. UV and anisomycin) was equivalent in the two cell lines, calcium-dependent JNK activation was 5-fold greater in GN4, correlating with CADTK activation. In contrast to JNK, the thapsigargin-dependent calcium signal did not activate mitogen-activated protein kinase and Ang II-dependent mitogen-activated protein kinase activation was not correlated with CADTK activation. Finally, while some stress-dependent activators of the JNK pathway (NaCl and sorbitol) stimulated CADTK, others (anisomycin, UV, and TNFα) did not. In summary, cells expressing CADTK/PYK2 appear to have two alternative JNK activation pathways: one stress-activated and the other calcium-dependent.

Published
1996

34. Angiotensin II Activates at Least Two Tyrosine Kinases in Rat Liver Epithelial Cells

Author

Ruth Chen Dy, Thomas L. Dawson, Lee M. Graves, William R. Huckle, H. Shelton Earp, and Xiong Li

Subjects
biology, Tyrosine phosphorylation, Cell Biology, Protein tyrosine phosphatase, Biochemistry, Molecular biology, Receptor tyrosine kinase, chemistry.chemical_compound, chemistry, ROR1, biology.protein, Janus kinase, Molecular Biology, Tyrosine kinase, Platelet-derived growth factor receptor, Proto-oncogene tyrosine-protein kinase Src
Abstract

In rat liver epithelial cell lines (WB or GN4), angiotensin II (Ang II) stimulates cytosolic tyrosine kinase activity, in part, through a calcium-dependent mechanism. In other cell types, selected hormones that activate Gi- or Gq-coupled receptors stimulate the soluble tyrosine kinase, p125FAK. Immunoprecipitation of p125FAK from Ang II-activated GN4 cells demonstrated a doubling of p125FAK kinase activity. However, an additional Ang II-activated tyrosine kinase (or kinases) representing the majority of the total activity was detected when the remaining cell lysate, immunodepleted of p125FAK, was reimmunoprecipitated with an anti-phosphotyrosine antibody. Cytochalasin D pretreatment blocks G-protein receptor-dependent tyrosine phosphorylation in Swiss 3T3 cells. While cytochalasin D decreased the Tyr(P) content of 65-75-kDa substrates in Ang II-treated GN4 cells, it did not diminish tyrosine phosphorylation of 115-130-kDa substrates, again suggesting activation of at least two tyrosine kinase pathways in GN4 cells. To search for additional Ang II-activated enzymes, we used molecular techniques to identify 20 tyrosine kinase sequences in these cell lines. None was the major cytosolic enzyme activated by Ang II. Specifically, JAK2, which had been shown by others to be stimulated by Ang II in smooth muscle cells, was not activated by Ang II in GN4 cells. Finally, we purified Tyr(P)-containing tyrosine kinases from Ang II-treated cells, using anti-Tyr(P) and ATP affinity resins; 80% of the tyrosine kinase activity migrated as a single 115-120-kDa tyrosine-phosphorylated protein immunologically distinct from p125FAK. In summary, Ang II activates at least two separate tyrosine kinases in rat liver epithelial cells; p125FAK and a presumably novel, cytosolic 115-120-kDa protein referred to as the calcium-dependent tyrosine kinase.

Published
1995

35. Calcium-dependent increase in tyrosine kinase activity stimulated by angiotensin II

Author

Ruth Chen Dy, H S Earp, and W R Huckle

Subjects
medicine.medical_specialty, Time Factors, Protein tyrosine phosphatase, In Vitro Techniques, Receptor tyrosine kinase, Internal medicine, medicine, Animals, Phosphorylation, Tyrosine, Kinase activity, Phosphotyrosine, Cells, Cultured, Multidisciplinary, Epidermal Growth Factor, biology, Angiotensin II, Protein-Tyrosine Kinases, Phosphoproteins, Rats, Cell biology, Enzyme Activation, Endocrinology, Liver, Mitogen-activated protein kinase, biology.protein, Calcium, Tyrosine kinase, Platelet-derived growth factor receptor, Research Article
Abstract

The cellular effects of numerous hormones and neurotransmitters, including the vasoactive agents angiotensin II (AngII) and [Arg8]vasopressin, are mediated in part by protein-serine threonine kinases activated by increase of cytosolic Ca2+ concentration. In this study, we have tested the ability of Ca(2+)-mobilizing agents to activate cellular tyrosine kinases. Treatment of intact GN4 liver epithelial cells with AngII rapidly (less than or equal to 15 sec) increased tyrosine kinase activity measured either in unfractionated cell lysates or in anti-phosphotyrosine immune complexes from detergent-solubilized cells. Increased phosphorylation of the exogenous substrate poly(Glu80Tyr20) (3- to 4-fold over control) by immunoprecipitated kinases closely paralleled the time- and dose-dependence of the appearance of tyrosine phosphoproteins in intact cells. This effect of AngII was mimicked by thapsigargin, a Ca(2+)-elevating tumor promoter. The ability of AngII, but not epidermal growth factor, to increase tyrosine kinase activity was blocked in cells loaded with the Ca2+ chelator bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid. Dephosphorylation of immunoprecipitated proteins by tyrosine phosphatase treatment was accompanied by a 60-70% loss in in vitro kinase activity, suggesting that the AngII-sensitive kinase(s) are activated by phosphorylation in intact cells. These findings demonstrate a link between two widely occurring signaling pathways, the tyrosine kinases and the Ca2+ second-messenger system, and suggest the possible involvement of Ca(2+)-activated tyrosine kinases in the endocrine actions of AngII and [Arg8]vasopressin.

Published
1992

36. Interactions between Two Cytoskeleton-associated Tyrosine Kinases: Calcium-dependent Tyrosine Kinase and Focal Adhesion Tyrosine Kinase

Author

Lee M. Graves, H. Shelton Earp, William G. Cance, Ruth Chen Dy, and Xiong Li

Subjects
PTK2, Protein tyrosine phosphatase, SRC Family Tyrosine Kinase, SH2 domain, Biochemistry, Receptor tyrosine kinase, Gene Expression Regulation, Enzymologic, Cell Line, src Homology Domains, chemistry.chemical_compound, Animals, Humans, Phosphorylation, Molecular Biology, Cytoskeleton, Binding Sites, biology, Chemistry, Autophosphorylation, Tyrosine phosphorylation, Cell Biology, Protein-Tyrosine Kinases, Cell biology, Rats, Enzyme Activation, Focal Adhesion Kinase 2, src-Family Kinases, Focal Adhesion Kinase 1, Focal Adhesion Protein-Tyrosine Kinases, Mutation, biology.protein, Mutagenesis, Site-Directed, Calcium, Vanadates, biological phenomena, cell phenomena, and immunity, Cell Adhesion Molecules, Proto-oncogene tyrosine-protein kinase Src
Abstract

The calcium-dependent tyrosine kinase (CADTK), also known as Pyk2/RAFTK/CAKbeta/FAK2, is a cytoskeleton-associated tyrosine kinase. We compared CADTK regulation with that of the highly homologous focal adhesion tyrosine kinase (FAK). First, we generated site-specific CADTK mutants. Mutation of Tyr402 eliminated autophosphorylation and significantly decreased kinase activity. Mutation of Tyr881, a putative Src kinase phosphorylation site predicted to bind Grb2, had little effect on CADTK regulation. Src family tyrosine kinases resulted in CADTK tyrosine phosphorylation even when co-expressed with the Tyr402/Tyr881 double mutant, suggesting that Src/Fyn etc. phosphorylate additional tyrosine residues. Interestingly, CADTK tyrosine-phosphorylated FAK when both were transiently expressed, but FAK did not phosphorylate CADTK. Biochemical experiments confirmed direct CADTK phosphorylation of FAK. This phosphorylation utilized tyrosine residues other than Tyr397, Tyr925, or Tyr576/Tyr577, suggesting that new SH2-binding sites might be created by CADTK-dependent FAK phosphorylation. Last, expression of the CADTK carboxyl terminus (CRNK) abolished CADTK but not FAK autophosphorylation. In contrast, FAK carboxyl terminus overexpression inhibited both FAK and CADTK autophosphorylation, suggesting that a FAK-dependent cytoskeletal function may be necessary for CADTK activation. Thus, CADTK and FAK, which both bind to some, but not necessarily the same, cytoskeletal elements, may be involved in coordinate regulation of cytoskeletal structure and signaling.

Published
1999
Full Text
View/download PDF

41. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Author

Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG, Smaldone, Marc C, Kutikov, Alexander, Egleston, Brian L, Canter, Daniel J, Viterbo, Rosalia, Chen, David Y T, Jewett, Michael A, Greenberg, Richard E, and Uzzo, Robert G

Abstract

Background: The authors systematically reviewed the literature and conducted a pooled analysis of studies on small renal masses who underwent active surveillance to identify the risk progression and the characteristics associated with metastases.Methods: A search of the MEDLINE database was performed to identify all clinical series that reported the surveillance of localized renal masses. For studies that reported individual-level data, clinical and radiographic characteristics of tumors without progression were compared with the characteristics of tumors that progressed to metastases.Results: Eighteen series (880 patients, 936 masses) met screening criteria; and, among these, 18 patients were identified who had tumors that progressed to metastasis (mean, 40.2 months). Six studies (259 patients, 284 masses) provided individual-level data for pooled analysis. At a mean (± standard deviation) follow-up of 33.5 ± 22.6 months, the mean initial greatest tumor dimension was 2.3 ± 1.3 cm, and mean linear growth rate was 0.31 ± 0.38 cm per year. Sixty-five masses (23%) exhibited zero net growth under surveillance, and none of those masses progressed to metastasis. A pooled analysis revealed increased age (age 75.1 ± 9.1 years vs 66.6 ± 12.3 years; P = .03), an initial greatest tumor dimension (4.1 ± 2.1 cm vs 2.3 ± 1.3 cm; P < .0001), initial estimated tumor volume (66.3 ± 100.0 cm(3) vs 15.1 ± 60.3 cm(3) ; p = .0001), linear growth rate of (0.8 ± 0.65 cm per year vs 0.3 ± 0.4 cm per year; P = .0001), and a volumetric growth rate of 27.1 ± 24.9 cm(3) per year (vs 6.2 ± 27.5 cm(3) per year; P < .0001) in the progression cohort.Conclusions: A substantial proportion of small renal masses remained radiographically static after an initial period of active surveillance. Progression to metastases occurred in a small percentage of patients and generally was a late event. The current results indicated that, in patients who have competing health risks, radiographic surveillance may be an acceptable initial approach, and delayed intervention may be reserved for patients who have tumors that exhibit significant linear or volumetric growth. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

43. Mechanical strain induces Cx43 expression in spinal ligament fibroblasts derived from patients presenting ossification of the posterior longitudinal ligament.

Author

Yang HS, Lu XH, Chen DY, Yuan W, Yang LL, Chen Y, He HL, Yang, Hai-Song, Lu, Xu-Hua, Chen, De-Yu, Yuan, Wen, Yang, Li-Li, Chen, Yu, and He, Hai-Long

Abstract

Ossification of the posterior longitudinal ligament (OPLL) is characterized by ectopic bone formation in spinal ligaments. Some evidence indicates that mechanical strain can lead to the development of OPLL, although the signaling mechanism is not fully understood. Connexin43 (Cx43), a gap-junction protein, has been shown to be of particular importance in bone formation. We hypothesized that Cx43 may play an important role in the signal transmission induced by mechanical strain during the development of OPLL. To explore this possibility, we cultured fibroblasts from spinal ligaments of OPLL and non-OPLL patients and preloaded mechanical stretch onto the cells via a Flexercell 4000 Tension Plus system. We evaluated expression changes in osteocalcin (OCN), alkaline phosphatase (ALP), type I collagen (COL I) and Cx43 via semi-quantitative RT-PCR and western blotting at 12 and 24 h after mechanical strain application in contrast to static conditions. We observed a significant gene up-regulation of OCN, ALP and COL I and Cx43 protein in OPLL cells after mechanical strain application, but no changes in non-OPLL cells. Notably, after RNA interference targeting Cx43 was performed in OPLL cells, we found that there were no significant changes in the expressions of OCN, ALP, COL I and Cx43 after the mechanical strain was applied for 24 h. Thus, we propose that the increase in Cx43 expression induced by mechanical strain in OPLL cells plays an important role in the progression of OPLL. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

46. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation

Author

H Kaiser, D. J. Fuller, Hayden G. Braine, William H. Burns, George W. Santos, Michael L. Graham, Wingard, Chen Dy, A. M. Yeager, and Philip J. Burke

Subjects
business.industry, Marrow transplantation, Incidence (epidemiology), Immunology, Congenital cytomegalovirus infection, Retinitis, Cell Biology, Hematology, Autologous bone, medicine.disease, Biochemistry, Cytomegalovirus infection, surgical procedures, operative, Bone transplantation, Medicine, Autogenous bone, business
Abstract

Cytomegalovirus (CMV) infection was detected in 65 of 143 (45%) autologous bone marrow transplant (BMT) patients. CMV pneumonitis occurred in only 2% of the patients and CMV retinitis occurred in none. Infection occurred in half of the 40 initially seronegative patients and 47% of the 94 initially seropositive patients. Among initially seropositive patients, platelet recovery was slower in infected patients than in those not infected (97 v 35 days median, P = .003), and neutrophil recovery was slightly delayed in infected patients (31 days v 24 days, P = .02). Although the incidence of CMV infection was comparable in autologous and allogeneic BMT patients, CMV pneumonitis was less frequent in autologous BMT patients (2% v 12%, P less than .001). The risk for CMV pneumonitis in autologous BMT patients was comparable with that in allogeneic BMT patients without graft-v-host disease (GVHD) (2% v 6%), but significantly lower than the risk in allogeneic BMT patients with GVHD (2% v 23%, P less than .001).

Published
1988

47. Interstitital Pneumonitis After Allogeneic Bone Marrow Transplantation NINE-YEAR EXPERIENCE AT A SINGLE INSTITUTION

Author

M. B. Sostrin, Wingard, R. Saral, Chen Dy, William E. Beschorner, George W. Santos, E. D. Mellits, Huibert M. Vriesendorp, and W. H. Burns

Subjects
Adult, Male, medicine.medical_specialty, Cyclophosphamide, Pulmonary Fibrosis, Statistics as Topic, Graft vs Host Disease, Cancer Care Facilities, Lower risk, Gastroenterology, Risk Factors, Idiopathic pneumonia syndrome, Internal medicine, medicine, Humans, Aplastic anemia, Bone Marrow Transplantation, Maryland, business.industry, Incidence (epidemiology), General Medicine, Total body irradiation, medicine.disease, Leukemia, surgical procedures, operative, Cytomegalovirus Infections, Female, Factor Analysis, Statistical, business, Immunosuppressive Agents, Busulfan, medicine.drug
Abstract

Of 386 patients with allogeneic bone marrow transplants (BMT) treated during a 9-year interval, 166 developed interstitial pneumonitis (IP). Idiopathic and cytomegalovirus (CMV) IP constituted 90% of the 113 cases in which tissue was examined. Risk factors for IP overall were acute graft-versus-host disease (AGVHD), remote transplant date, the diagnosis of leukemia, and GVHD prophylaxis with agents other than cyclosporine. Risk factors for CMV IP were pre-transplant CMV seropositivity, CMV excretion, age greater than 10 years, AGVHD, GVHD prophylaxis with agents other than cyclosporine, and a remote transplant date. Patients transplanted for aplastic anemia were at lower risk for idiopathic IP than those transplanted for leukemia. The incidence of IP in patients given busulfan plus cyclophosphamide was equivalent to that in patients receiving cyclophosphamide plus total body irradiation. The incidence of idiopathic IP remained constant over this 9-year period while CMV IP declined significantly.

Published
1988

48. Effects of Selective Depletion of Luteinizing Hormone and Testosterone on the Pituitary-Gonadal Axis

Author

H. G. Madhwa Raj, M. R. Sairam, Martin Dym, and Ruth Chen Dy

Subjects
Antiserum, endocrine system, medicine.medical_specialty, Adult male, Urology, Endocrinology, Diabetes and Metabolism, Hypothalamic–pituitary–gonadal axis, Pituitary gonadal axis, Biology, Low testosterone levels, FSH secretion, Endocrinology, Reproductive Medicine, Internal medicine, medicine, Luteinizing hormone, hormones, hormone substitutes, and hormone antagonists, Testosterone
Abstract

Daily treatment of adult male rats with an antiserum specific to LH caused a precipitious fall in plasma testosterone levels by 18 h. The levels of FSH were unchanged thoughout the observation period (72 h). The fact that such low testosterone levels did not cause any alteration in FSH secretion strengthens the possibility that other factors (e. g. inhibin) may be involved in modulating FSH levels, in addition to testosterone.

Published
1978

49. Structural and Functional Regression of Polycystic Ovaries by Danazol

Author

Shailaja G. Raj, Madhwa H.G. Raj, Luther M. Talbert, and Ruth Chen Dy

Subjects
Danazol, Estrous cycle, endocrine system, medicine.medical_specialty, medicine.drug_class, business.industry, Obstetrics and Gynecology, Polycystic ovary, Endocrinology, Reproductive Medicine, Estrogen, Internal medicine, Follicular phase, medicine, Functional regression, Luteinizing hormone, business, hormones, hormone substitutes, and hormone antagonists, Testosterone, medicine.drug
Abstract

The effects of danazol on ovarian steroidogenesis and follicular size was studied in androgen-sterilized rats bearing polycystic ovaries. Daily treatment with 4 or 20mg of the drug caused a reduction in ovarian weight and regression of cystic follicles. Serum levels of luteinizing hormone (LH), testosterone, and estrogen were significantly decreased. The persistent estrus smears were changed to diestrus, indicating inhibition of estrogenic activity.

Published
1981

50. Vanadate stimulates tyrosine phosphorylation of two proteins in Raji human lymphoblastoid cell membranes

Author

Ruth Chen Dy, Kathy S. Austin, H. Shelton Earp, and R. A. Rubin

Subjects
Biophysics, Protein tyrosine phosphatase, SH2 domain, Biochemistry, Receptor tyrosine kinase, Cell Line, chemistry.chemical_compound, Protein phosphorylation, Structural Biology, Genetics, Humans, Vanadate, Phosphorylation, Molecular Biology, biology, Cell Membrane, Membrane Proteins, Tyrosine phosphorylation, Vanadium, Cell Biology, Protein-Tyrosine Kinases, Burkitt Lymphoma, Molecular biology, Tyrosine-specific kinase, Enzyme Activation, chemistry, Membrane protein, biology.protein, Electrophoresis, Polyacrylamide Gel, Lymphocyte, Vanadates, Protein Kinases, Platelet-derived growth factor receptor
Abstract

A membrane fraction from Raji human lymphoblastoid cells exhibited tyrosine-specific kinase activity. Vanadate increased tyrosine phosphorylation up to 5-fold; serine and threonine phosphorylation were unchanged. The stimulation was detectable within 15 s at 0 degrees C and at concentrations of vanadate (0.3 and 1.0 microM) present in normal tissues and blood. The tyrosine phosphorylation of two substrates, M1 61 000 and 55 000, was dependent upon vanadate and incorporation into these substrates represented the majority of the vanadate-sensitive tyrosine phosphorylation.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results